At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 142 enrolled
Drug / intervention
Weight-based dexamethasone dosedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Open Investigation Determining Steroid Dose (ROIDS-Dose)
In Brief
A Phase 3 clinical trial evaluating Weight-based dexamethasone dose for Covid19. Completed, enrolled 142 participants across 1 site.
Detailed Summary
Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against COVID-19 pneumonia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedApr 2021
Primary CompletionJan 2022
Study CompletionMar 2022
TodayJul 2026
First PostedApr 8, 2021
Enrollment StartMar 19, 2021
Primary CompletionJan 25, 2022
Study CompletionMar 29, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.2 years ago
Interventions
Weight-based dexamethasone dosedrug
Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure